Klinicheskaya farmakologiya sartanov:klass-effekt i farmakodinamicheskieosobennosti preparatov
- Authors: Zakharova NV1, Kuz'mina-Krutetskaya SR1
-
Affiliations:
- Issue: Vol 8, No 3 (2011)
- Pages: 10-16
- Section: Articles
- URL: https://journals.eco-vector.com/2075-082X/article/view/33096
- DOI: https://doi.org/10.26442/SG33096
- ID: 33096
Cite item
Full Text
Abstract
References
- Brunner HR, Kirsman DJ, Sealey JE et al. Hypertension of renal origin:evidence for two different mechanisms. Science 1971; 174: 1344-6.
- Brunner HR, Gavras H, Laragh JH et al. Angiotensin-II blockade in man by Sar1-Ala8-angiotensin II for understanding and treatment of high blood pressure. Lancet 1973; 2: 1045.
- Bergsma DJ, Ellis C, Kumar C et al. Cloning and characterization of a human angiotensin II type 1 receptor. Biochem Biophys Res Commun 1992; 183: 989-95.
- Леонова М.В., Белоусов Ю.Б., Штейнберг Л.Л. и др. Фармакоэпидемиология артериальной гипертонии в России (по результатам фармакоэпидемиологического исследования ПИФАГОР III. Рос. кардиол. журн. 2011; 2: 9-17.
- Dzau VJ, Sasamura H, Hein L. Heterogeneity of angiotensin synthetic pathways and receptor subtypes: physiological and pharmacological implications. J Hypertens 1993; 11 (Suppl. 3): S13-S22.
- Urata K, Kinoshita A, Misono K et al. Identification of a highly specific chymase as the major angiotensin-forming enzyme in the human heart. J Biol Chem 1990; 265: 22348-82.
- Burnier M. Angiotensin II Type 1 Receptor Blockers. Circulation 2001; 103: 904-12.
- Ohkubo N, Matsubara H, Nozawa Y et al. Angiotensin type 2 receptors are re-expressed by cardiac fibroblasts from failing myopathic hamster hearts and inhibit cell growth and fibrillar collagen metabolism. Circulation 1997; 96: 3954-62.
- Ritter JM. Angiotensin converting enzyme inhibitors and angiotensin receptor blockers in hypertension. BMJ 2011; 342: d1673 doi: 10.1136/bmj.d1673.
- Miura S, Karnik S and Saku K. Review: Angiotensin II type 1 receptor blockers: class effects versus molecular effects. J Renin-Angiotensin-Aldosterone Syst 2011; 12: 1.
- Doulton T, He F and MacGregor G. MacGregor Angiotensin Receptor Blockade in Hypertension. Systematic Review of Combined Angiotensin-Converting Enzyme Inhibition and Angiotensin Receptor Blockade in Hypertension. Hypertension 2005; 45: 880-6.
- Azilsartan medoxomil (Edarbi) the eighth ARB. Med Lett Drugs Ther 2011; 16 (53): 1364.
- Le MT, De Backer JP, Hunyady L et al. Ligand binding and functional properties of human angiotensin AT1 receptors in transiently and stably expressed CHO-K1 cells. Eur J Pharmacol 2005; 513 (1-2): 35-45.
- Van Liefde I, Vauquelin G. Sartan-AT1 receptor interactions: in vitro evidence for insurmountable antagonism and inverse agonism. Mol Cell Endocrinol 2009; 302 (2): 237-43.
- Bhuiyan MA, Ishiguro M, Hossain M et al. Binding sites of valsartan, candesartan and losartan with angiotensin II receptor 1 subtype by molecular modeling. Life Sci 2009; 85 (3, 4): 136.
- Ojima M, Igata H, Tanaka M et al. In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies. J Pharmacol Exp Ther 2011; 336 (3): 801-8.
- Westerink J, Visseren F. Cardiovasc Pharmacological and non-pharmacological interventions to influence adipose tissue function. Cardiovasc Diabetol 2011; 10: 13.
- Bangalore S. Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials. BMJ 2011; 342: d2234.
- Ishii H, Tsukada T, Yoshida M. Angiotensin II Type-I Receptor Blocker, Candesartan, Improves Brachial-Ankle Pulse Wave Velocity Independent of Its Blood Pressure Lowering Effects in Type 2 Diabetes Patients. J Soc Int Med 2008; 47: 2013-8.
- Izuhara Y, Sada T, Yanagisawa H et al. A novel Sartan derivative with very low angiotensin II type 1 receptor affinity protects the kidney in type 2 diabetic rats. Arterioscler Thromb Vasc Biol 2008; 28 (10): 1767-73.
- Mancia G, De Backer G, Dominiczak A et al. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens.
- Чазова И.Е., Ратова Л.Г., Бойцов С.А., Небиеридзе Д.В. (рабочая группа). Диагностика и лечение артериальной гипертензии (Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов). Системные гипертензии. 2010; 3: 5-27.
- Matchar DB, McCrory DC, Orlando LA et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med 2008; 148: 16.
- Granger CB, McMurray JJ, Yusuf S et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362: 772.
- Lee VC, Rhew DC, Dylan M et al. Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. Ann Intern Med 2004; 141: 693.
- Eklind-Cervenka M, Benson L, Dahlström U et al. Association of candesartan vs losartan with all-cause mortality in patients with heart failure. JAMA 2011; 305: 175.
- Weir RA, McMurray JJ, Puu M et al. Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial. Eur J Heart Fail 2008; 10 (2): 157-63.
- Drazner MH, Rame JE, Marino EK et al. Increased left ventricular mass is a risk factor for the development of a depressed left ventricular ejection fraction within five years: the Cardiovascular Health Study. J Am Coll Cardiol 2004; 43: 2207.
- Klingbeil AU, Schneider M, Martus P et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115: 41.
- Os I, Franco V, Kjeldsen SE et al. Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the Losartan Intervention for Endpoint Reduction in Hypertension Study. Hypertension 2008; 51: 1103.
- Cuspidi C, Negri F, Zanchetti A. Angiotensin II receptor blockers and cardiovascular protection: focus on left ventricular hypertrophy regression and atrial fibrillation prevention. Vasc Health Risk Manag 2008; 4: 67.
- Yusuf S, Pfeffer MA, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362: 777.
- Yamashita T, Inoue H, Okumura K et al. Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study). Europace 2011; 13 (4): 473-9.
- Tissot AC, Maurer P, Nussberger J et al. Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet 2008; 371: 821.
Supplementary files
![](/img/style/loading.gif)